Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival

被引:237
作者
Fulford, Laura G.
Reis-Filho, Jorge S.
Ryder, Ken
Jones, Chris
Gillett, Cheryl E.
Hanby, Andrew
Easton, Douglas
Lakhani, Sunil R.
机构
[1] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
[2] Ludwig Inst Canc Res, London W1W 7BS, England
[3] Guys Hosp, Hedley Atkins Imperial Canc Res Fund Brest Pathol, London SE1 9RT, England
[4] Univ Leeds, St James Univ Hosp, Acad Unit Pathol, Leeds LS9 7TF, W Yorkshire, England
[5] Strangeways Res Lab, Canc Res Campaign Genet Epidemiol Unit, Cambridge CB1 8RN, England
[6] Univ Queensland, Sch Med, Brisbane, Qld 4006, Australia
[7] Queensland Inst Med Res, Brisbane, Qld 4006, Australia
关键词
D O I
10.1186/bcr1636
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Cytokeratin (CK) 14, one of several markers expressed in normal myoepithelial/basal cells, is also expressed in a proportion of breast carcinomas. Previous studies have suggested that expression of such 'basal' markers predicts different biological behaviour, with more frequent lung and brain metastases and poorer prognosis than other carcinomas. Methods We performed CK14 immunohistochemistry on 443 grade III invasive ductal carcinomas with extended clinical follow-up ( mean 116 months), and we correlated CK14 immunopositivity ( basal-like phenotype) with clinicopathological criteria. Results Eighty-eight of 443 (20%) tumours showed CK14 expression. CK14-positive tumours were more likely to be oestrogen receptor-negative ( p < 0.0001) and axillary node-negative ( p = 0.001) than were CK14-negative cases. CK14-positive cases developed less bone and liver metastases ( hazard ratio [HR] 0.49, p = 0.01, and HR 0.53, p = 0.035, respectively) but more frequent brain metastases ( HR 1.92, p = 0.051). In patients without metastatic disease, disease-free survival in CK14-positive cases was significantly better than in CK14-negative cases ( HR 0.65, p = 0.005). In patients with metastatic disease, however, CK14 positivity was associated with a poorer prognosis ( HR 1.84, p = 0.001). The overall survival in CK14-positive and - negative patients was similar at 5 years (60% and 59%, respectively), but the long-term survival was better in CK14-positive patients ( HR 0.69, p = 0.02). Conclusion These results demonstrate that basal-like tumours differ in their biological behaviour from other tumours, with a distinct pattern of metastatic spread. Compared to other grade III tumours, basal-like tumours appear to have a relatively good long-term survival but survival after metastases is poor.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
    Abd El-Rehim, DM
    Ball, G
    Pinder, SE
    Rakha, E
    Paish, C
    Robertson, JFR
    Macmillan, D
    Blamey, RW
    Ellis, IO
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (03) : 340 - 350
  • [2] [Anonymous], 2003, PATHOL GENET
  • [3] Basal-like breast carcinomas: clinical outcome and response to chemotherapy
    Banerjee, S.
    Reis-Filho, J. S.
    Ashley, S.
    Steele, D.
    Ashworth, A.
    Lakhani, S. R.
    Smith, I. E.
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (07) : 729 - 735
  • [4] Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Carey, Lisa A.
    Perou, Charles M.
    Livasy, Chad A.
    Dressler, Lynn G.
    Cowan, David
    Conway, Kathleen
    Karaca, Gamze
    Troester, Melissa A.
    Tse, Chiu Kit
    Edmiston, Sharon
    Deming, Sandra L.
    Geradts, Joseph
    Cheang, Maggie C. U.
    Nielsen, Torsten O.
    Moorman, Patricia G.
    Earp, H. Shelton
    Millikan, Robert C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21): : 2492 - 2502
  • [5] The influence of familial and hereditary factors on the prognosis of breast cancer
    Chappuis, PO
    Rosenblatt, J
    Foulkes, WD
    [J]. ANNALS OF ONCOLOGY, 1999, 10 (10) : 1163 - 1170
  • [6] IMMUNOLOCALIZATION OF A HUMAN BASAL EPITHELIUM SPECIFIC KERATIN IN BENIGN AND MALIGNANT BREAST DISEASE
    DAIRKEE, SH
    LJUNG, BM
    SMITH, H
    HACKETT, A
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1987, 10 (01) : 11 - 20
  • [7] Expression of luminal and basal cytokeratins in human breast carcinoma
    El-Rehim, DMA
    Pinder, SE
    Paish, CE
    Bell, J
    Blamey, R
    Robertson, JFR
    Nicholson, RI
    Ellis, IO
    [J]. JOURNAL OF PATHOLOGY, 2004, 203 (02) : 661 - 671
  • [8] ELLIS IO, 1992, HISTOPATHOLOGY, V20, P479
  • [9] PATHOLOGICAL PROGNOSTIC FACTORS IN BREAST-CANCER .1. THE VALUE OF HISTOLOGICAL GRADE IN BREAST-CANCER - EXPERIENCE FROM A LARGE STUDY WITH LONG-TERM FOLLOW-UP
    ELSTON, CW
    ELLIS, IO
    [J]. HISTOPATHOLOGY, 1991, 19 (05) : 403 - 410
  • [10] Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer
    Foulkes, WD
    Stefansson, IM
    Chappuis, PO
    Bégin, LR
    Goffin, JR
    Wong, N
    Trudel, M
    Akslen, LA
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (19) : 1482 - 1485